



id.DRIVE

Master Protocol for Study Contributors

Brand-specific respiratory syncytial virus vaccine effectiveness in Europe

A contribution of id.DRIVE, a public-private partnership to facilitate the conduct of observational studies on infectious diseases, vaccines, related preventive measures, therapeutics, and diagnostics for infectious diseases.

Version 3.0

21 February 2025

AUTHORS AND CONTRIBUTORS

Contributing organisations to this Master Protocol and contact persons

Organisation	Contact person	e-mail address
P95	Kaatje Bollaerts	kaatje.bollaerts@p-95.com
FISABIO	Brenda Marquina Sánchez	brenda.marquina@fisabio.es
GlaxoSmithKline Pfizer	Miloje Savic	miloje.x.savic@gsk.com
AstraZeneca	Clinical Study Information Center	information.center@astrazeneca.com

Abbreviations: FISABIO, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana; P95, P95 Clinical and Epidemiology Services

DOCUMENT HISTORY

Version control table for this Master Protocol

Version	Version date	Reason for new version
1.0	21 March 2024	First version of protocol created
2.0	7 June 2024	In this version modified-SARI definition is updated to include patients hospitalised with suspicion of a respiratory infection.
3.0	21 February 2024	Amendments: <ul style="list-style-type: none"> • change study status wording from “non-interventional study” to “observational study” • update of the list of current id.DRIVE Partners • primary and secondary objectives text clarified • exploratory objective added • sensitivity analysis details added • clarification to specimen collection and laboratory testing • overall reorganization of sections to improve readability • update of the section “Research methods” and section “Limitations of the research methods” to provide more details on the study • added Table “Overview of the assays performed at each Study Contributor” and Table “Data sources per Study Contributor for exposures, outcomes (i.e., endpoints) and covariates” • update of Table “Study covariates and health care use” to align with eCRF • frailty as additional covariate at the Henri Modor Study Contributor added to section “Covariates” • added section “Data sources” • only for sites in the United Kingdom: addition of an exclusion criteria for patients who are deemed mentally incapacitated to provide informed consent (UK Mental Capacity Act 2005)

Abbreviations: eCRF, electronic case report form; SARI, severe acute respiratory infection.

BACKGROUND OF THIS MASTER PROTOCOL

This Master Protocol describes a European, observational study to estimate the effectiveness of vaccines against respiratory syncytial virus (RSV). Of interest is the effectiveness against hospitalisation due to severe acute respiratory infection (SARI) caused by RSV. The study is a multi-country, hospital-based study with test-negative case-control (TNCC) design.

This Master Protocol will be used to create Study Requestor (i.e., Pharmaceutical Company Partner)-specific protocols that meet the requirements of the Study Requestors. From the Study Requestor-specific protocols, Study Contributor (i.e., study site)-specific protocols will be developed, which detail the data collection and requirements at the specific Study Contributor level. This Master Protocol is set up to harmonise study methods (e.g., study objectives, study participant inclusion/exclusion criteria, case definitions, exposures, endpoints, and data collection) and to mutualise healthcare provider/Study Contributor resources.

This Master Protocol has been developed by the id.DRIVE public-private partnership (<https://iddrive.eu>). The id.DRIVE partnership intends to conduct studies on infectious diseases, vaccines, related preventive measures and therapeutics (e.g., antivirals and monoclonal antibodies), and diagnostics for infectious diseases. Current id.DRIVE members are FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Spain), P95 Clinical and Epidemiology Services (Belgium), AstraZeneca (United Kingdom), Novavax (United States) and Pfizer (United States).

The outline of this Master Protocol was inspired by the Preparing for RSV Immunisation and Surveillance in Europe (PROMISE) project (<https://imi-promise.eu>).

1 TITLE PAGE

Abbreviated study title	Brand-specific respiratory syncytial virus vaccine effectiveness in Europe
Full study title	Brand-specific respiratory syncytial virus (RSV) vaccine effectiveness in Europe - A contribution of id.DRIVE, a public-private partnership to facilitate the conduct of observational studies on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases in Europe
HMA/EMA catalogue number	EUPAS1000000035
Master Protocol version	3.0
Date of protocol version	21 February 2021
Active substance(s)	Study Requestor RSV vaccine
Study status	Observational
Research question and objectives	<p><u>Primary objective:</u></p> <p>To estimate respiratory syncytial virus (RSV) vaccine effectiveness (VE) for the RSV vaccine against hospitalisation due to laboratory-confirmed RSV infection in older adult patients with modified severe acute respiratory infection (SARI), eligible to receive the vaccine.</p> <p><u>Secondary objectives:</u></p> <p>As objective 1, but stratified by/subgroup analyses among:</p> <ul style="list-style-type: none"> • RSV subtype A and B (objective 2.1) • Populations of special interest (e.g., age groups, sex, chronic medical condition risk groups, among the immunocompetent, among those with co-administered vaccines) (objective 2.2) • Time since vaccination (objective 2.3) • History and time since prior RSV infection within the last 12 months (objective 2.4) • Country and study site (objective 2.5) <p>As objective 1 but using severity endpoints (objective 2.6):</p> <ul style="list-style-type: none"> • Modified-SARI severity level¹ <p><u>Exploratory objectives:</u></p> <p>Descriptive analysis of vaccinated and unvaccinated cases and controls: demographic, clinical, severity, length of hospital stay and, laboratory characteristics (objective 3)</p>
Country(ies) of study	France, Germany, Spain, Italy, and UK. Additional countries may be included in the course of the study.

¹ SARI severity levels are defined by hospital outcome (intensive care unit [ICU] admission; in-hospital death), respiratory support and/or length of hospital stay. As an additional indicator of severity at hospitalisation and throughout hospitalisation, progression risk is defined as proportion of in-hospital deaths and proportion of ICU admissions among all hospitalised SARI patients.

2 TABLE OF CONTENTS

AUTHORS AND CONTRIBUTORS	2
DOCUMENT HISTORY	3
BACKGROUND OF THIS MASTER PROTOCOL.....	4
1 TITLE PAGE	5
2 TABLE OF CONTENTS	6
3 LIST OF TABLES	9
4 LIST OF FIGURES	9
5 GLOSSARY	10
6 ABBREVIATIONS.....	13
7 RESPONSIBLE PARTIES.....	15
7.1 Study Sponsor: P95 Clinical and Epidemiology Services	15
7.2 Principal Investigator.....	15
8 ABSTRACT	16
9 RATIONALE AND BACKGROUND	25
10 RESEARCH QUESTION AND OBJECTIVES	27
10.1 Research question.....	27
10.2 Research objectives.....	27
10.2.1 Primary objective	27
10.2.2 Secondary objectives.....	27
10.2.3 Exploratory objectives:.....	27
11 RESEARCH METHODS	28
11.1 Study design	28
11.2 Study duration.....	28
11.3 Countries, Study Contributors and data collection	28
11.4 Study population	29
11.4.1 Patient identification	29
11.4.2 Hospitalised patient	29
11.4.3 Modified-SARI definition	29
11.4.4 Inclusion criteria.....	30
11.4.5 Exclusion criteria.....	31
11.4.6 Specimen collection and laboratory testing	31
11.5 Study endpoints.....	32
11.5.1 Primary endpoint: laboratory-confirmed RSV.....	32
11.5.2 Cases ('test-positive cases').....	32

11.5.3	Controls ('test-negative control')	32
11.5.4	Secondary endpoints.....	33
11.6	Exposure (RSV vaccination).....	34
11.6.1	Exposure definitions.....	34
11.6.2	Exposure ascertainment.....	34
11.7	Covariates	35
11.8	Data sources	37
11.9	Sample size considerations.....	38
11.10	Data management.....	38
11.10.1	Data management at Study Contributor level.....	38
11.10.2	Data flow	38
11.11	Data analysis.....	39
11.11.1	Context information	39
11.11.2	Attrition diagram.....	39
11.11.3	Descriptive analysis of demographics and baseline characteristics.....	39
11.11.4	Statistical analyses.....	39
12	QUALITY MANAGEMENT.....	43
12.1	Independent Scientific Committee.....	43
12.2	Quality Assurance and Audit Committee	43
12.3	Monitoring.....	43
12.4	Data quality checks at central level.....	44
13	LIMITATIONS OF THE RESEARCH METHODS.....	45
14	ETHICAL AND REGULATORY CONSIDERATIONS, RETENTION OF DATA AND OF BIOLOGICAL SAMPLES	48
14.1	Guiding principles.....	48
14.2	Ethics approval.....	48
14.3	Informed consent.....	48
14.4	Independent ethics committee/Institutional review board.....	49
14.5	Participant's confidentiality	49
14.6	Changes to the protocol.....	49
14.7	Secondary data use.....	50
15	STUDY MANAGEMENT AND LOGISTICAL ASPECTS.....	51
15.1	Training	51
15.2	Data capture.....	51
15.3	Retention	51

15.4	Discontinuation of study participation/Withdrawal from the study	51
15.5	Study termination.....	52
16	REPORTING AND DISSEMINATION OF RESULTS.....	53
16.1	Study protocol	53
16.2	Management and reporting of adverse events/adverse reactions	53
16.3	Progress, interim and final reports.....	53
16.4	Publication.....	53
17	FUNDING.....	55
18	REFERENCES	56
	ANNEX 1: SAMPLE SIZE CALCULATIONS, TECHNICAL SPECIFICATIONS	1
	ANNEX 2: PATIENTS LACKING CAPACITY	1

3 LIST OF TABLES

Table 2. Overview of the assays performed at each Study Contributor.....	32
Table 3. The list of collected study variables with description.....	35
Table 4. Data sources per Study Contributor for exposures, outcomes (i.e., endpoints) and covariates.....	38

4 LIST OF FIGURES

Figure 1. Schedule of activities for the primary data collection during the study period	29
--	----

5 GLOSSARY

Term	Description
Action	means all the activities, including research activities, carried out by the Partners under the Consortium Agreement as described in further detail in the Governance Charter.
Co-Coordiators	means FISABIO and P95, both Partners, that are the Co-coordinators.
Core Platform Partners	means the group of Partners that are not Pharmaceutical Company Partners.
Consortium	means the group of Partners that are parties to the Consortium Agreement. The Consortium has no separate legal personality.
Consortium Agreement	means the agreement and all of its appendices (including the Governance Charter), together with amendments signed by all the authorised representatives of the Partners.
COVIDRIVE	means the public-private partnership for the estimation of brand-specific COVID-19 vaccine effectiveness in Europe organised under the Consortium Agreement.
Data Collection	means a data collection under a single or under multiple protocols (incl. Master Protocol(s)) for the purpose of Primary Data Use.
Governance Charter	means a document, appended to the Consortium Agreement, which provides details on the governance of the Action: objectives, guiding principles, stakeholders, roles and responsibilities, legal and regulatory environment, communication and expected tasks and Deliverables that will guarantee an efficient and fair execution of the Action. The Governance Charter is made available by the Co-Coordiators upon request.
id.DRIVE	means the public-private partnership for conducting observational studies on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases in Europe organised under the Consortium Agreement. For the avoidance of doubt, as of January 2024 COVIDRIVE became a part of

id.DRIVE as described in further detail in the id.DRIVE Governance Charter.

Independent Scientific Committee (ISC)

means the body consisting of a limited number of external experts with relevant experience/expertise in the field of infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases. Scientific experts representing each of the Co-coordinators act as the secretariat of the ISC.

Informed Consent Form

means the document to inform the Study participants of the purpose of the Data Collection, data handling and possible risks and benefits of participating in the Study in lay language and document the voluntary decision of the Study participant to participate in the Study. The Informed Consent Form is adapted to national requirements, translated into the language of the Study participant and approved by the ethics committee of the Study Contributor at which the Study is performed.

Master Protocol

means the protocols agreed by the Partners to harmonise Data Collection and to ensure the potential mutualisation of e.g., Study Contributor resources.

Partner

means a legal entity signatory of the Consortium Agreement. Partners are either Core Platform Partners or Pharmaceutical Company Partners.

Pharmaceutical Company Partner

means a Partner that is a pharmaceutical company.

Primary Data Use

means the use of patient's data for the purpose of a single Study or multiple Studies defined prior to id.DRIVE Data Collection.

Pseudonymised data

means data that is processed in such a manner that the personal data can no longer be attributed to a specific person but still allows for re-identification in combination with additional information, in line with the provisions of the European Union General Data Protection Regulation (the "GDPR").

Quality Assurance and Audit Committee (QAAC)

means the committee responsible for the quality management and auditing of the Studies, composed of one quality assurance expert from each Pharmaceutical Company Partners and one

quality assurance expert from the Co-coordinators. The Co-Coordinators act as the secretariat of the QAAC.

Secondary Data Use

means the use of patients' data that has already been collected for the purpose of a single Study or multiple Studies as defined after Data Collection.

Study

means a study on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases requested by a specific Study Requestor through Primary Data Use or Secondary Data Use to be performed in the framework of the Action.

Study Contributor

or "Study Site" or "Site", means an institution that collects/owns data of interest for Studies and that signs a Study Contributor Agreement with P95 after being selected via a study-specific selection process.

Study Requestor

means the Partner that requests to perform a specific Study.

Study Results Publication

means a scientific publication reporting on the Study including all Study objectives identified in the individual Study protocol(s).

Study Sponsor

means the organisation which takes on the responsibility – on behalf of the Consortium – to initiate, manage and finance the Studies, as well as ensuring the operational/administrative coordination of the network of Study Contributors. The Study Sponsor is P95.

Study Team (ST)

means the team that carries out the conduct of the Study. For Primary Data Use Studies, the Study Team includes experts from the Co-Coordinators, Study Contributors and Study Requestors.

- The Restricted Study Team (Restricted ST) is made up of experts from the Co-Coordinators and Study Contributors.
- The Full Study Team (Full ST) is the Restricted ST plus the experts from the Study Requestors.

6 ABBREVIATIONS

ARI	Acute respiratory infection
BiPAP	Bi-level positive airway pressure
BMI	Body mass index
CCA	Complete case analysis
CI	Confidence interval
CIRI-IT	Centro Interuniversitario per la Ricerca sull'Influenza e le altre Infezioni
CIOMS	Council for International Organisations of Medical Sciences
COPD	Chronic obstructive pulmonary disease
COVID-19	Coronavirus disease 2019
CPAP	Continuous positive airway pressure
DMP	Data management plan
EC	Ethics committee
ECDC	European Centre for Disease Prevention and Control
ECMO	Extracorporeal membrane oxygenation
eCRF	Electronic case report form
ED	Emergency department
EDC	Electronic data capture
EMA	European Medicines Agency
ESKD	End-stage kidney disease
ESLD	End-stage liver disease
EU	European Union
FDA	United States Food and Drug Administration
FISABIO	Fundación para Fomento de Investigación Sanitaria y Biomédica la Comunidad Valenciana
GAM	Generalised additive model
GDPR	General Data Protection Regulation
GEE	Generalised estimating equations
GEP	Good Epidemiological Practice
GLM	Generalised linear model
GOLD	Global Initiative for Chronic Obstructive Lung Disease
GPP	Good Publication Practice
GSK	GlaxoSmithKline
HEV	Human enterovirus
HIV	Human immunodeficiency virus
HMA	Heads of Medicines Agencies
hMPV	Human metapneumovirus
HRV	Human rhinovirus
ICD	The International Classification of Diseases
ICF	Informed consent form
ICMJE	International Committee of Medical Journal Editors
ICU	Intensive care unit

IEC	Independent ethics committee
IEE	Independence estimating equations
IRB	Institutional review board
ISC	Independent scientific committee
LAR	Legally acceptable representative
LTCF	Long-term care facility
MAH	Marketing authorisation holder
MHRA	Medicines and Healthcare products Regulatory Agency
N	Number
N/A	Not applicable
NHS	National health service
OR	Odds ratio
P	Prevalence
PA	Population-averaged (odds ratio)
PROMISE	Preparing for RSV Immunisation and Surveillance in Europe
QAAC	Quality assurance and audit committee
RADT	Rapid antigen detection test
RE-MA	Random-effects meta-analysis
RNA	Ribonucleic acid
RR	Relative risk
RSV	Respiratory syncytial virus
RT-PCR	Reverse transcription polymerase chain reaction
rVE	Relative vaccine effectiveness
SAE	Serious adverse event
SAP	Statistical analysis plan
SARI	Severe acute respiratory infection
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
SIV	Site initiation visit
SS	Subject-specific (odds ratio)
ST	Study team
TBC	To be confirmed
THL	Finnish Institute for Health and Welfare
TMA	Transcription-mediated amplification
TNCC	Test-negative case-control
US	United States
VAHNSI	Valencia Hospital Network for the Study of Influenza and Other Respiratory Viruses
VE	Vaccine effectiveness
WHO	World Health Organisation

7 RESPONSIBLE PARTIES

7.1 Study Sponsor: P95 Clinical and Epidemiology Services

Thomas Verstraeten
P95 Clinical and Epidemiology Services (P95)
Diestsevest 125
3000 Leuven
BELGIUM
thomas.verstraeten@p-95.com

7.2 Principal Investigator

Kaatje Bollaerts
P95 Clinical and Epidemiology Services (P95)
Diestsevest 125
3000 Leuven
BELGIUM
kaatje.bollaerts@p-95.com

8 ABSTRACT

Background

- RSV is a common cause of respiratory tract infections. Older adults are at higher risk for hospitalisation and death due to RSV. RSV vaccines have received European Union (EU) marketing authorisation to prevent RSV-associated lower respiratory tract disease in adults aged 60 years and older.
 - Pharmaceutical Company Partners may use the id.DRIVE public-private partnership to conduct its future VE studies which may be part of regulatory submissions depending on the outcome of regulatory interactions.
 - This study protocol details an observational study through the id.DRIVE partnership to estimate the effectiveness of and RSV vaccine against RSV-related modified severe acute respiratory infection (SARI) hospitalisations in older adults.
-

Research question

The study aims to continuously monitor VE of an RSV vaccine against RSV-related modified-SARI hospitalisations in older adults using a network of hospitals across Europe.

Research objectives

Primary objective: to estimate the RSV vaccine VE against hospitalisation due to laboratory-confirmed RSV infection in older adult patients with modified SARI, eligible to receive the vaccine.

Secondary objectives:

1. As objective 1, but stratified by/subgroup analysis among:

- RSV subtype A and B (objective 2.1)
 - Populations of special interest (e.g., age groups, sex, chronic medical condition risk groups, among the immunocompetent, among those with co-administered vaccines) (objective 2.2)
 - Time since vaccination (objective 2.3)
 -
 - History and time since prior RSV infection within the last 12 months (objective 2.4)
 - Country and study site (objective 2.5)
-

2. As objective 1, but using severity endpoints (objective 2.6):

- Modified-SARI severity level²

Exploratory objectives:

- Descriptive analysis of vaccinated and unvaccinated cases and controls: demographic, clinical, severity, length of hospital stay and, laboratory characteristics (objective 3)
-

Study methods

Study design: The study is a multi-country, multi-centre, hospital-based test-negative case-control (TNCC) study.

Data sources: A combination of primary and secondary data collection will be used to obtain the relevant data.

Study duration: The study provides continuous (i.e., year-round) RSV surveillance, with a study period lasting minimum 12 months and expected to last up to 36 months, with possibility to extend.

Countries: The study will be conducted in multiple countries in Europe³.

Study population: Individuals presenting at the participating hospitals during the study period who are hospitalised, meet the modified-SARI patient case definition and meet the inclusion/exclusion criteria.

Hospitalised patient: A patient is considered hospitalised when having at least one overnight stay at the hospital ward (from date of first contact with the hospital to discharge), irrespective of the setting in which they received care (e.g., if they received care in the Emergency Department (ED) for the duration of their hospitalisation, or if they first received care in ED and were then admitted to the ward). In case of referral to another hospital, the date of hospital admission is defined as the date of first admission.

Modified-SARI patient is here defined as a person hospitalised with a suspicion of a respiratory infection with at least one of the following symptoms:

- cough
- shortness of breath
- fever ($\geq 38^{\circ}\text{C}$)

with symptom onset within the last 10 days prior to hospital admission. This modified-SARI definition is adapted from the latest European Centre for Disease

² SARI severity levels are defined by hospital outcome (intensive care unit [ICU] admission; in-hospital death), respiratory support and/or length of hospital stay. As an additional indicator of severity at hospitalisation and throughout hospitalisation, progression risk is defined as proportion of in-hospital deaths and proportion of [ICU] admissions among all hospitalised SARI patients.

³ The list of countries will be extended as the id.DRIVE network grows.

Prevention and Control (ECDC) coronavirus diseases 2019 (COVID-19) SARI case definition⁴ to include at minimum a 'suspicion of a respiratory infection'. Alternative definitions will be explored by means of sensitivity analyses.

Inclusion and exclusion criteria:

Hospitalised modified-SARI patients must fulfil all of the following inclusion criteria and none of the exclusion criteria to be included in the study as study participants:

- Inclusion criteria:
 - The patient is ≥60 years old at the time of admission to the hospital.
 - The patient is eligible to receive vaccination against RSV for adults (not maternal vaccination) depending on the vaccination programme in the patient's country of residence.
 - Informed consent is obtained from the patient or, when accepted by the Ethics Committee, from the patient's legally acceptable representative(s) (LAR(s)) prior to enrolment.
- Exclusion criteria:
 - The patient is unable or unwilling to provide the protocol-required respiratory specimen(s) for any reason.
 - *Only for sites in the United Kingdom:* deemed mentally incapacitated to provide informed consent due to a condition other than SARI, as defined by the UK Mental Capacity Act 2005.

Study outcomes of interest (i.e., endpoints)

The primary endpoint is:

- hospitalisation due to laboratory-confirmed RSV infection in patients with modified SARI aged 60+ who were eligible for vaccination in their country.

Cases ('test-positive cases): Study participants who meet the modified-SARI hospitalised patient definition AND have at least one respiratory sample testing positive for RSV using reverse transcription polymerase chain reaction (RT-PCR) or similar molecular assay, with specimens collected within 10 days prior and up to 72 hours after hospital admission. Test-positive cases may include laboratory-confirmed coinfections.

Alternative case definitions can be explored by means of sensitivity analyses.

Controls (test-negative controls): Study participants who meet the modified-SARI hospitalised patient definition AND have all respiratory samples testing negative for

⁴ EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (2021). *ECDC Technical report: Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0, 2021*. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf>. [Accessed: 24-11-2022].

RSV using RT-PCR or similar molecular assays, with specimen(s) collected between 10 days prior to and up to 72 hours after hospital admission.

All patients who tested negative for RSV prior to hospitalisation will be re-tested at hospital admission. Alternative control definitions can be explored by means of sensitivity analyses.

RSV testing:

Nasopharyngeal and/or oropharyngeal swabs are preferred for testing and will be used for main analysis. Other respiratory specimens are accepted (e.g. sputum or induced sputum, bronchoalveolar lavage, or endotracheal, tracheal or nasopharyngeal aspirates and other), when collected as part of patient diagnostic work-up. A sensitivity analysis will be performed if a substantial number of such other respiratory samples are collected.

RT-PCR or another ribonucleic acid (RNA) amplification system with at least the same sensitivity as RT-PCR (e.g., transcription-mediated amplification [TMA]) must be used for the detection of RSV, SARS-CoV-2, and influenza. Information on the RSV subtypes will be collected on all confirmed RSV cases when sample quality allows.

Secondary endpoints are:

- as the primary but stratified by RSV subtype (A and B).
- as the primary but stratified by care setting (hospitalised without intensive care unit (ICU) admission or in-hospital death, ICU admission without in-hospital death, in-hospital death).
- as the primary but stratified by type of highest level of respiratory support received (oxygen therapy, non-invasive ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO)).

as the primary but stratified by length of hospital stay (categories based on number of days).

Exposure (RSV vaccination)

- Vaccinated with the RSV vaccine during the study period of interest:
vaccinated with exposure of interest: e.g., single dose/primary vaccination/at least one dose of the RSV vaccine during the study period of interest, within the appropriate timeframe for the product to be **effective**, e.g., ≥ 15 days, prior to modified-SARI symptom onset, where day 1 is the date of vaccination.
 - Unvaccinated during the study period of interest:
did not receive any RSV vaccine (investigational or licensed) during the study period of interest.
 - Recently vaccinated with the RSV vaccine:
vaccinated with exposure of interest: e.g., single dose/primary vaccination/at least one dose» of the RSV vaccine during the study period of interest,
-

within the appropriate timeframe for the product to be **ineffective**, e.g., <15 days, prior to modified-SARI symptom onset.

- Other: Additional vaccine exposure definitions might be defined depending on the real-life use of the RSV vaccines.

Covariates

Variables that are potential confounders and/or effect modifiers will be collected at Study Contributors. These include: age, sex, history of selected morbidities of interest (e.g., asthma, lung disease, cardiovascular disease, hypertension, chronic liver and renal disease, diabetes, obesity, cancer, neurological disorders, chronic haematological disorders and immunocompromising conditions)⁵, vaccination against other respiratory pathogens (including SARS-CoV-2, influenza, *Streptococcus pneumoniae*), history of prior RSV infection, prior modified-SARI hospitalisation(s), chronic oxygen supplemental therapy, respiratory support, ICU admission, in-hospital death, post-discharge destination, length of hospital stay, treatment received prior to or during current hospitalisation for the management of current modified-SARI episode, medicinal product received as prophylaxis of RSV infection prior to current modified-SARI episode, laboratory results for included viral respiratory pathogens (including RSV, influenza, SARS-CoV-2, hMPV and other), rapid antigen detection test results for RSV, body mass index (BMI), clinical frailty scale and long-term care facility (LTCF) residence.

Data sources, data collection

The study uses a combination of primary (e.g., specific laboratory results, vaccine cards) and secondary data sources (e.g., existing hospital databases, vaccine registries and linked data).

After study enrolment, data will be collected directly from the patient or by consulting medical records. Information to be collected at a minimum includes date of modified-SARI symptom onset, date of hospitalisation, respiratory specimen testing results, and information on the potential confounders and effect modifiers of interest.

The RSV vaccine exposure status date(s) of vaccination(s) and data source will be ascertained by consulting vaccination registries, vaccination cards or medical records (depending on the country and region). Where needed, treating physician or other health care professionals will be contacted to obtain additional information. Verbal reports by patients will not be accepted.

Context information on national/regional vaccination recommendations and RSV vaccine label information will be collected from external sources.

⁵ Definitions of the comorbidities of interest will be specified in detail as part of the eCRF.

Sample size

The sample size requirements strongly depend on RSV circulation, the case-control ratio, overall RSV vaccination coverage and share of the different RSV vaccine brands. Due to the nature of the TNCC design, all cases and controls are recruited and data on them are collected. This is a key aspect of the TNCC and additionally crucial for surveillance use-cases. If balancing of case-control ratios is desired, this can be handled at the analysis stage for brand-specific analyses (for example by matching). As such, the sample size requirements will be different for the different vaccine brands. In case the parameter settings used for these sample size calculations are very different from what is observed in the study, the sample size calculations will be updated accordingly.

To account for potential loss of precision due to covariate adjustment in regression models, the required sample size estimate will be inflated by a factor fixed in advance. Commonly, a value of 20% is used, although other values – e.g., 50% or 100% (i.e., double) – can also be used, albeit with an associated impact on data collection costs. For example, if the uninflated sample size is estimated to be 1,000 SARI patients, the required sample size will be reported as 1,200 SARI patients, assuming an inflation factor of 20%.

Data management

Data collected at Study Contributors will be checked for quality and transferred to a dedicated, secured central server hosted by P95. A data management plan (DMP) will be written prior to the start of the data collection. The DMP describes all functions, processes, responsibilities and specifications for data collection, cleaning, and validation.

An expert consensus group to classify exposure groups will consist of members of the Study Teams. In case of disagreement, the Independent Scientific Committee (ISC) of id.DRIVE will be consulted.

Statistical analysis

Descriptive analyses will be performed to describe the study population, the RSV seasonality and the RSV vaccination coverage for the brand of interest.

VE is defined as $(1 - OR) \times 100\%$, where OR denotes the (exposure) odds ratio, comparing the confounder-adjusted odds of vaccination among RSV-positive study participants to the odds of vaccination among RSV-negative study participants. The analysis will evaluate VE among those vaccinated with the RSV vaccine versus those unvaccinated. Those who were recently vaccinated with the RSV vaccine, or vaccinated with other RSV vaccine(s) will be excluded from all VE analyses.

VE estimates will be adjusted for symptom-onset date at minimum, and additionally the following confounders – age, sex, and comorbidities (e.g. number of chronic conditions). Other potential covariates may be identified and included in the model using model building techniques. Confounder adjustments are usually achieved through inclusion of the relevant terms in the logistic regression models, with (penalised) spline terms for calendar time and age. However, other methods may be considered as well.

Differences between countries and Study Contributor are a potential source of heterogeneity and confounding. This can be accounted for using generalised

additive models (GAM) or generalised estimating equation (GEE) models with clusters being defined at the Study Contributor level. If some Study Contributors are networks that have hospitals which are very different (e.g. geographically separated), then clustering could be defined at the hospital level for these networks. However, similarities between these hospitals may remain due to being part of the same hospital network, in which case these would not be treated as being independent of each other.

An important choice is whether the exposure odds ratios are desired to have a subject-specific (SS) or population-averaged (PA) interpretation. The SS OR compares odds of vaccination among the RSV-positive cases to the odds of vaccination among the RSV-negative controls from the same Study Contributor (conditional on other covariates) and necessitates the inclusion of a fixed-effect or a random-effect term for Study Contributor or via a meta-analysis. The PA OR compares the odds of vaccination among the RSV-positive cases across the Study Contributors to the odds of vaccination among RSV-negative controls across the Study Contributors (conditional on other covariates) and is commonly obtained from a GEE model. Care should be taken with regards to method selection (estimators for point-estimates and standard errors) to avoid biased VE estimates when the clustering variable is a potential confounder.

Matched cohort and matched analysis can be considered if sample size allows, e.g., matching by Study Contributor and hospital admission date.

Sensitivity analyses will be conducted as appropriate. A complete and detailed statistical analysis plan (SAP) will be developed prior to the conduct of the analysis.

Study limitations

Study limitations include:

- Time-varying confounders and effect modifiers: these include seasonality, RSV subtypes, levels of vaccine-induced and natural immunity in the population, timing of RSV vaccination programmes and prioritisation strategies due to limited supply. Their complex interplay makes it challenging to disentangle waning of vaccine-induced immunity, differences in VE against different RSV subtypes, and infection-acquired immunity.
 - Misclassification of disease status: RSV RT-PCR assays have a high specificity and sensitivity, but a single respiratory swab may miss 50% of RSV infections among older adults. RT-PCR sensitivity is influenced by several factors, including operator sampling technique, type of specimen, number of specimens, and timing of sampling. To explore any potential bias due to disease misclassification, sensitivity analyses regarding time between symptom onset and swabbing are performed.
 - Prior infection: Infection-acquired immunity is an effect modifier of VE. Although information on past RSV infection is collected in this study, prior infection is highly likely to be undocumented (e.g., asymptomatic disease).
 - Unaccounted for confounders: these include ethnicity and socio-economic status. In general, results from this study will be highly specific to its population, and this will need to be carefully considered when generalising or comparing results.
-

Ethical considerations

Study Contributor-specific protocols (developed by the Study Contributors themselves, based on this protocol) will be submitted to relevant independent ethics committee(s) (IECs) following local regulations. Informed consent will be obtained from participants/guardians as specified by the national/regional IEC.

Reporting

Progress reports will be prepared every two months. Interim analyses will be planned as appropriate. A final study report will be written.

Interim reports and the final report will be submitted to the European Medicines Agency (EMA) and other competent regulatory bodies (e.g., Medicines and Healthcare products Regulatory Agency (MHRA), U.S. Food and Drug Administration (FDA) by the marketing authorisation holder (MAH) to meet regulatory requirements.

Dissemination

The generic Master Protocol on which this Study Contributor protocol is based (Master Protocol Brand-specific RSV VE in Europe, V3.0), and its significant amendments, will be listed in the Heads of Medicines Agencies/European Medicines Agency (HMA/EMA) catalogue of real-world data studies. Study reports, each for a specific vaccine brand, will likewise be listed in the HMA/EMA catalogue and will be submitted to peer-reviewed open-source international journal(s).

Updates on study progress will be posted on the id.DRIVE website (<https://iddrive.eu>).

Funding

This Master Protocol V3.0 has been developed by the id.DRIVE public-private partnership, which has received funds from AstraZeneca, GSK (GlaxoSmithKline), Janssen, Novavax, Pfizer, and Valneva, leveraging public health capacity from Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and existing infrastructure at P95. Other partners (vaccine companies or other institutes) might join id.DRIVE at later stages. The execution of the study will be funded by pharmaceutical companies which may join progressively. This specific funding will be transparently acknowledged in all communications.

id.DRIVE public-private partnership

id.DRIVE is an open public-private partnership. Current members are FISABIO (Spain), P95 Clinical and Epidemiology Services (Belgium), AstraZeneca (United Kingdom), Novavax (United States), and Pfizer (United States). Past members are the Finnish Institute for Health and Welfare (THL, Finland), CureVac (Germany), GSK (Belgium), Janssen (Belgium), Moderna (United States), Sanofi (France), Valneva (Austria), and Bavarian Nordic (Denmark). id.DRIVE aims to facilitate the conduct of observational studies on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases in Europe.

Study status

Observational

Study sponsor

P95 Clinical and Epidemiology Services

9 RATIONALE AND BACKGROUND

RSV is a common pathogen causing respiratory tract infections [3], and its burden is increasingly recognised among older adults. In high-income countries, RSV-related annual hospitalisations were estimated to be 787,000 in 2021 [4], with an annual hospitalisation rate of 145 per 100,000 for RSV-associated acute respiratory infections in adults ≥ 60 years of age [5]. In older adults, RSV case fatality proportion was estimated to be 8% [6], with both hospitalisation and mortality rates found to be comparable to influenza [7]. Adults with underlying medical conditions [8, 9] and frailty [10, 11] are at higher risk for hospitalisation and death, potentially due to exacerbation of existing chronic conditions, such as chronic obstructive pulmonary disease and congestive heart failure.

RSV has two main subtypes: A and B, with either of them predominating in a given season, although they may circulate simultaneously in the population [12]. In temperate climates, RSV typically follows a distinct seasonal pattern, with a peak between December and February. Reverse transcriptase-polymerase chain reaction (RT-PCR) and (PCR-based) point-of-care tests are the gold-standard for the diagnosis of RSV infections. Rapid antigen detection tests (RADT) are also used for RSV diagnosis, as they require less time and resources, but have a lower sensitivity [13]. Clinical severity is strongly associated with viral load, which declines seven days after infection [14].

The development of safe and efficacious vaccination products is essential to address the public health impact of RSV-associated illness. As of 02 December 2024, two protein-based vaccines, Arexvy® (GSK) and Abrysvo® (Pfizer), and one mRNA vaccine, mRESVIA® (Moderna) have been approved for use in older adults in the EU.

Although the efficacy of RSV vaccines has been investigated thoroughly during clinical trials, continuous evaluation of product-specific VE under real-world conditions once used as part of the national immunisation programmes remains crucial. Real-world studies allow for the evaluation of more rare outcomes such as hospitalisation, ICU admission and mortality. Additionally, duration of vaccine-induced protection, differential VE based on RSV subtypes, and VE in risk groups such as immunocompromised or patients with chronic conditions can be assessed.

id.DRIVE, a not-for-profit public-private partnership launched in January 2024, is leveraging COVIDRIVE, a public-private partnership that addressed the joint need to monitor coronavirus disease 2019 (COVID-19) vaccination programmes for public health institutes and assess brand-specific COVID-19 VE for vaccine companies as part of their regulatory obligations. id.DRIVE will facilitate the conduct of studies on infectious diseases' burden, -vaccines, -preventive measures, and -therapeutics (e.g. antivirals, monoclonal antibodies) in the European region. Current id.DRIVE members are FISABIO (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Spain), P95 Clinical and Epidemiology Services (Belgium), AstraZeneca (United Kingdom), Novavax (United States), and Pfizer (United States). The Pharmaceutical Company Partners will use this partnership to conduct its future RSV VE studies as part of its regulatory obligations.

This protocol describes an observational study to estimate the effectiveness of RSV vaccines against RSV-related hospitalisations through the id.DRIVE partnership. This study is a multi-centre, hospital-based, case-control study with test-negative controls (TNCC) design. The hospital-based TNCC design is efficient for studying rare outcomes, allows potentially for patient-reported or healthcare provider-reported data collection, and can minimise disease misclassification and confounding by healthcare-seeking behaviour. Data will be collected through a wide network of hospitals located in several European countries.

The outline of this protocol was adapted from previous protocols from the Preparing for RSV Immunisation and Surveillance in Europe (PROMISE) project (<https://imi-promise.eu>) and the COVIDRIVE project (<https://iddrive.eu/>).



10 RESEARCH QUESTION AND OBJECTIVES

10.1 Research question

The study aims to continuously monitor VE of an RSV vaccine against RSV-related modified-SARI hospitalisations in older adults using a network of hospitals across Europe.

10.2 Research objectives

10.2.1 Primary objective

To estimate an RSV vaccine VE against hospitalisation due to laboratory-confirmed RSV infection in older adult patients with modified SARI, eligible to receive the vaccine.

10.2.2 Secondary objectives

As objective 1, but stratified by/subgroup analysis among:

- RSV subtype A and B (objective 2.1)
- Populations of special interest (e.g., age groups, sex, chronic medical condition risk groups, among the immunocompetent, among those with co-administered vaccines) (objective 2.2)
- Time since vaccination (objective 2.3)
-
- History and time since prior RSV infection within the last 12 months (objective 2.4)
- Country and study site (objective 2.5)

As objective 1, but using severity endpoints (objective 2.6):

- Modified-SARI severity level⁶

10.2.3 Exploratory objectives:

Descriptive analysis of vaccinated and unvaccinated cases and controls: demographics, clinical, severity, length of hospital stay and laboratory characteristics (objective 3).

⁶ SARI severity levels are defined by hospital outcome (intensive care unit [ICU] admission; in-hospital death), respiratory support and/or length of hospital stay. As an additional indicator of severity at hospitalisation and throughout hospitalisation, progression risk is defined as proportion of in-hospital deaths and proportion of [ICU] admissions among all hospitalised SARI patients.

11 RESEARCH METHODS

11.1 Study design

This study is a multi-country⁷, multi-centre, hospital-based (optionally, matched) TNCC study.

A combination of primary and secondary data collection will be used to obtain the relevant data.

11.2 Study duration

The study provides continuous (i.e., year-round) RSV surveillance, with a study period lasting minimum 12 months and expected to last up to 36 months, with possibility to extend.

11.3 Countries, Study Contributors and data collection

The study will be conducted in multiple countries in Europe that have introduced an RSV vaccine into their immunisation programs. These will likely include the United Kingdom, France, Germany, Italy and Spain. Depending on the vaccine's roll-out, other countries might be selected.

In this study, the term 'Study Contributor' is used in lieu of 'study site'. The participating Study Contributors are either individual hospitals or hospital networks. The data collection will be a prospective data collection from primary data sources (e.g., specific laboratory results) and secondary data sources (e.g., existing hospital databases, vaccine registries and linked data). Retrospective data collection will be considered to allow capture of whole epidemiological year data in Study Contributors with late set-up.

⁷ The list of countries will be extended as the id.DRIVE network grows.

The schedule of activities (**Figure 1**) shows the primary data collected from subjects during the study period.




Figure 1. Schedule of activities for the primary data collection during the study period

11.4 Study population

11.4.1 Patient identification

Systematic screening of individuals presenting with respiratory symptoms at participating hospitals during the study period is organised. The study population consists of all individuals presenting at the participating hospitals during the study period who are hospitalised, meet the modified-SARI patients case definition (see **Section 11.4.2**) and meet the inclusion/exclusion criteria.

11.4.2 Hospitalised patient

A patient is considered hospitalised when having at least one overnight stay at the hospital ward (from date of first contact with the hospital to discharge), irrespective of the setting in which they received care (e.g., if they received care in the ED for the duration of their hospitalisation, or if they first received care in ED and were then admitted to a ward). In case of referral to another hospital, the date of hospital admission is defined as the date of first admission.

11.4.3 Modified-SARI definition

A modified-SARI patient is defined as a person hospitalised with a suspicion of a respiratory infection with at least one of the following symptoms:

- cough
- shortness of breath
- fever ($\geq 38^{\circ}\text{C}$)

with symptom onset within the last 10 days prior to hospital admission.

This modified-SARI definition is adapted from the latest ECDC coronavirus disease 2019 (COVID-19) SARI case definition [15], used in id.DRIVE to include at minimum a 'suspicion of a respiratory infection'. Sensitivity analysis will be done applying the WHO-RSV case definition⁸ and id.DRIVE case definition⁹.

Additionally, the International Classification of Diseases (ICD)-10 codes and corresponding definitions listed below could be used as a guideline to identify potential modified-SARI patients (i.e., for screening), if deemed appropriate at specific Study Contributors:

- J00-J06: Acute upper respiratory infections
- J21.0, J21.8, J21.9: Bronchiolitis
- J12-J18: Pneumonia
- J20-J22: Other acute lower respiratory infections
- J40-J47: Chronic lower respiratory diseases

Participants may be co-enrolled in interventional trials. The name of the trial will be collected, to allow for exclusion from specific analysis, where required, and will be prespecified in the SAP.

11.4.4 Inclusion criteria

Hospitalised modified-SARI patients must fulfil all of the following inclusion criteria to be included in the study as study participants:

- The patient is ≥60 years old at the time of admission to the hospital.
- The patient is eligible to receive vaccination against RSV for adults (not maternal vaccination) depending on the vaccination programme in the patient's country of residence.

⁸ A World Health Organisation (WHO)-expanded definition of RSV-SARI (severe disease – defined as requiring hospitalisation AND acute – defined as onset within the last 10 days AND respiratory infection – defined as having at least one of the following: shortness of breath or cough) will be used in sensitivity analyses. [Source: <https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance/case-definitions>]

⁹ An id.DRIVE definition of SARI (defined as requiring hospitalisation with a suspicion of a respiratory infection with symptom onset within the last 14 days prior to hospital admission, having at least one of the following symptoms: cough, shortness of breath, fever (≥ 38 C°) or sudden onset of anosmia, ageusia or dysgeusia) will be used in sensitivity analyses. This SARI definition is modified from the latest ECDC case definition (specifying "suspicion of respiratory infection"). EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (2023). Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 2.0. Available from: <https://www.ecdc.europa.eu/en/publications-data/core-protocol-ecdc-studies-covid-19-vaccine-effectiveness-against-0> [Accessed: 17-08-2023]].

- Informed consent is obtained from the patient or, when accepted by the Ethics Committee, from the patient's LAR(s) prior to enrolment.

11.4.5 Exclusion criteria

Hospitalised modified-SARI patients must not fulfil the following exclusion criterion to be included in the study as study participants:

- The patient is unable or unwilling to provide the protocol-required respiratory specimen(s) for any reason.
- *Only for sites in the United Kingdom:* As defined by the UK Mental Capacity Act 2025⁽¹⁾, patients who are deemed mentally incapacitated to provide informed consent due to a condition other than SARI will be excluded from the study.

⁽¹⁾ For the UK Mental Capacity Act 2025, a person is considered unable to consent if, at the time of consent, they can't make decisions for themselves because of mind or brain impairments (See ANNEX 2: PATIENTS LACKING CAPACITY).

11.4.6 Specimen collection and laboratory testing

To the extent possible, clinical specimens will be collected from all patients eligible for the study as part of routine clinical sampling for diagnostic work-up. However, depending on local practice, additional sampling for the purpose of the study may be required.

Nasopharyngeal and/or oropharyngeal swabs are preferred for testing and will be used for main analysis. Other respiratory specimens are accepted (e.g., sputum or induced sputum, bronchoalveolar lavage, or endotracheal, tracheal or nasopharyngeal aspirates and other), when collected as part of patient diagnostic work-up. A sensitivity analysis will be performed if a substantial number of such other respiratory samples are collected.

The respiratory samples will be tested within the local laboratory infrastructures of the participating Study Contributors, for at least SARS-CoV-2, influenza A/B and RSV A/B, and preferably also for *other viral respiratory pathogens* (this category includes adenovirus, parainfluenza 1-4, human metapneumovirus [hMPV], human rhinovirus [HRV], human enterovirus [HEV], human coronaviruses [229E/NL63/OC43/HKU1] and human bocavirus 1-4) by using validated reverse transcription polymerase chain reaction (RT-PCR) assays or another RNA amplification system with at least the same sensitivity as RT-PCR (e.g., transcription-mediated amplification [TMA]). RT-PCR assays must be used for the detection of at least RSV, SARS-CoV-2, and influenza.

Information on the RSV subtypes will be collected on all confirmed RSV cases when sample quality allows. Study Contributors will be requested to submit validation logs (summarising the quality check process, results, timing and certificates of analysis for assays performed) to the Study Team.

For every participating Study Contributor, the current laboratory assays and included pathogens are summarised in Table 1. Overview of the assays performed at each Study Contributor **Table 1**.

**Table 1. Overview of the assays performed at each Study Contributor**

Assay name	Study contributor name
SARS-CoV-2	X
Influenza A	X
Influenza A-H1	X
Influenza A-H3	X
Influenza B	X
RSV	X
RSV A/B	X
Adenovirus	X
Human Enterovirus	X
Human Rhinovirus	X
Parainfluenza 1-4	X
Human Bocavirus 1-4	X
Coronavirus 229E/NL63/OC43/HKU1	X
Human Metapneumovirus	X

Abbreviations: RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

11.5 Study endpoints

11.5.1 Primary endpoint: laboratory-confirmed RSV

The primary endpoint is hospitalisation due to laboratory-confirmed RSV infection in patients with modified SARI aged 60+ who were eligible for vaccination in their country.

11.5.2 Cases ('test-positive cases')

'Test-positive cases' are study participants who meet the modified-SARI hospitalised patient definition AND have at least one respiratory sample testing positive for RSV using RT-PCR or similar molecular assays, with specimens collected within 10 days prior and up to 72 hours after hospital admission. Test-positive cases may include laboratory-confirmed coinfections.

Alternative case definitions can be explored by means of sensitivity analyses (e.g., to exclude coinfections i.e., all respiratory samples testing positive for influenza, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], human metapneumovirus [hMPV] and/or other viral respiratory pathogens tested using RT-PCR).

11.5.3 Controls ('test-negative control')

'Test-negative controls' are study participants who meet the modified-SARI hospitalised patient definition AND have all respiratory samples testing negative for

RSV using RT-PCR or similar molecular assays, with specimen(s) collected between 10 days prior to and up to 72 hours after hospital admission. Test-negative controls may include study participants positive and/or negative for other pathogens based on specimen(s) collected between 10 days prior to and up to 72 hours after hospital admission.

All patients tested negative for RSV prior to hospitalisation will be re-tested at hospital admission. Alternative control definitions may be explored by means of sensitivity analyses (e.g., to also exclude all respiratory samples testing positive for influenza, SARS-CoV-2, hMPV and/or other viral respiratory pathogens tested using RT-PCR).

11.5.4 Secondary endpoints

The secondary endpoints in patients hospitalised with modified-SARI symptoms include:

- detection of RSV subtypes A and B
- modified-SARI severity level of study participants (both cases and controls), including respiratory support severity level

11.5.4.1 RSV subtypes

Hospitalisation due to laboratory-confirmed RSV infection by subtype (A and B) in patients with modified SARI.

Information on the RSV subtypes (A and B) will be collected to the extent possible, preferably on all confirmed RSV cases when sample quality allows.

11.5.4.2 Modified-SARI severity level

Severity will be assessed in three ways, 1) by care setting, 2) by respiratory support categories and by 3) length of hospital stay.

Care setting Hospitalisation with modified SARI due to laboratory-confirmed RSV infection by care setting using the following three mutually exclusive categories:

1. Hospital admission without ICU admission and without in-hospital death;
2. ICU admission without in-hospital death;
3. In-hospital death
 - a. during ICU stay
 - b. outside of ICU stay

11.5.4.2.1 Respiratory support

Hospitalisation due to laboratory-confirmed RSV infection with modified SARI by type of respiratory support (in increasing levels of support) using following categories:

1. No respiratory support;
2. Oxygen therapy (e.g., nasal cannula, mask);
3. Non-invasive ventilation (ventilatory support without tracheal intubation; e.g., high-flow nasal oxygen, Continuous Positive Airway Pressure [CPAP] or Bi-level Intermittent Positive Airway Pressure [BiPAP]);

4. Invasive mechanical ventilation (ventilatory support with tracheal intubation);
5. Extracorporeal membrane oxygenation (ECMO).

For each patient, the highest level of respiratory support ever received during the hospital stay will be reported.

11.5.4.2.2 Length of hospital stay

Hospitalisation due to laboratory-confirmed RSV infection with modified SARI by length of hospital stay (categories based on number of days).

11.6 Exposure (RSV vaccination)

11.6.1 Exposure definitions

11.6.1.1 *'Vaccinated with [RSV vaccine name] during the study period of interest'*

'Vaccinated' study participants were vaccinated with exposure of interest: e.g., single dose/primary vaccination/at least one dose of RSV vaccine of interest during the study period of interest, within the appropriate timeframe for the product to be **effective**, e.g., ≥ 15 days, prior to modified-SARI symptom onset, where day 1 is the date of vaccination.

11.6.1.2 *'Unvaccinated during the study period of interest'*

'Unvaccinated' study participants did not receive any RSV vaccine (investigational or licensed) during the study period of interest.

11.6.1.3 *'Recently vaccinated with [RSV vaccine name]'*

'Recently vaccinated' study participants were vaccinated with exposure of interest: e.g., single dose/primary vaccination/at least one dose of RSV vaccine of interest during the study period of interest, within the appropriate timeframe for the product to be **ineffective**, e.g., < 15 days, prior to modified-SARI symptom onset.

11.6.1.4 *Other*

Additional vaccine exposure definitions might be developed depending on the real-life use of the RSV vaccines.

11.6.2 Exposure ascertainment

Information on all prior RSV vaccine doses will be collected. Vaccination status, vaccination date, vaccine dose and vaccine name and brand information are required. Depending on the Study Contributor, the source for exposure ascertainment will be different and may include vaccination registries, medical records, or vaccination cards. Information on the source documentation of the exposure ascertainment will be collected.

Patients that cannot be classified into one of the exposure categories will be classified as unknown and excluded from the dataset. Those who were recently vaccinated

with the RSV vaccine, or vaccinated with other RSV vaccine will not be included in the VE analysis.

Context information on national/regional vaccination recommendations and RSV vaccine label information will be collected from external sources.

11.7 Covariates

The complete dataset can be found in the electronic case report form (eCRF) of the id.DRIVE common dataset and is summarised in **Table 2**. All variables are being collected for both prospective and retrospective subjects, if available.

Table 2. The list of collected study variables with description

Variable ¹⁰		Description
Age at hospital admission		Years, calculated based on date of birth and date of admission
Sex assigned at birth		Male, female
Chronic conditions*		
	Asthma	Binary If yes, subcategory 'Mild intermittent', 'Mild persistent', 'Moderate persistent', 'Severe persistent', 'No information'
	Lung disease	Binary If yes, subcategory 'COPD' and stage (GOLD I – IV, No information)
	Cardiovascular disease	Binary If yes, subcategory 'Congestive heart failure'
	Hypertension	Binary
	Chronic liver disease	Binary If yes, subcategory 'End-stage liver disease (ESLD)': 'No', 'Yes', 'No information'
	Chronic renal disease	Binary If yes, subcategory 'End-stage kidney disease (ESKD)': 'No', 'Yes but without dialysis', 'Yes and on dialysis', 'No information'
	Diabetes type I	Binary, if yes subcategory diabetic end organ damage: No, Yes, No information
	Diabetes type II	Binary, if yes subcategory diabetic end organ damage: No, Yes, No information
	Obesity	Binary
	Cancer	Binary

¹⁰ Some covariates might not be collected across all Study Contributors. This will be specified in the Study Requestor-specific protocol and SAP after completion of feasibility assessments.

Variable ¹⁰		Description
		If yes, specification of subcategories: 'Solid tumour', 'Haematological cancer', 'No information'. If solid tumour or haematological cancer is yes, further specification of cancer type to be selected from list.
	Immunodeficiency (or organ transplant)	Binary If yes, specification of subcategories: 'Solid organ or islets transplant', 'Hematopoietic stem cell transplantation', 'Primary immunodeficiency', 'Advanced or untreated human immunodeficiency virus (HIV) infection', 'Iatrogenic immunodeficiency', 'Other'. If solid organ or islets transplant is yes, specification of subcategories: 'Kidney', 'Liver', 'Intestines', 'Heart', 'Lung', 'Pancreas', 'Other', 'No information'
	Chronic haematological disorder (non-cancerous)	Binary
	Neurological disorder	Binary
Receiving chronic oxygen supplemental therapy		Binary (defined as oxygen used for at least 15 h per day in chronically hypoxaemic patients)
Body mass index (BMI)		Continuous
Clinical Frailty Scale[†]		Very fit, Fit, Managing well, Living with very mild frailty, Living with mild frailty, Living with moderate frailty, Living with severe frailty, Living with very severe frailty, Terminally ill, No information
Vaccination history RSV		Binary If yes, was it investigational RSV vaccine, brand, date, and source of information
Vaccination history COVID-19		Binary If yes, brand, date, and source of information
Vaccination history influenza		Binary, within 12 months prior to the modified-SARI hospital admission If yes, brand, date, and source of information
Vaccination history pneumococcus		Binary, at least one vaccination in the past If yes, brand, date, and source of information
Long-term care facility residence		Binary, if no specification of residential situation before hospitalisation: 'Home', 'Home with nursing care', 'Transfer from another hospital', 'Rehabilitation centre', 'Nursing home', 'Other', 'No information'
History of RSV in the current season before symptom onset leading to this hospitalisation		Binary If yes, date.
Prior modified-SARI hospitalisation episode in previous 12 months		Binary, If yes, time since most recent prior modified-SARI hospitalisation
Month and year of prior SARI episode		Month and year
Respiratory support		'None', 'Oxygen therapy', 'Non-invasive ventilation', 'Invasive mechanical ventilation', 'Extracorporeal membrane oxygenation (ECMO)', 'No information'
Hospital admission date		Date
Hospital discharge date		Date

Variable ¹⁰	Description
ICU admission	Binary, date of admission, date of discharge
In-hospital death	Binary, date of in-hospital death
Post-discharge destination	'Home', 'Home with nursing care', 'Transfer to another hospital', 'Rehabilitation centre', 'Nursing home or other long-term care facility', 'Other', 'No information'
Length of hospital stay	Days, continuous
Treatments received during hospital stay for the management of modified-SARI episode	'Antibiotics', 'Antiviral drug(s)', 'Corticosteroid(s)', 'Immune modulator(s)', 'Anti-RSV antibodies', 'Other monoclonal antibodies', 'None of the above'. Brand name, if anti-RSV antibodies received during hospital stay
Treatments received prior to hospital admission for the management of current modified-SARI episode	'Antibiotics', 'Antiviral drug(s)', 'Corticosteroid(s)', 'Anti-RSV antibodies', 'Other monoclonal antibodies', 'None of the above'. Brand name, if anti-RSV (or other monoclonal) antibodies received during hospital stay
Medicinal product for the prevention of RSV infection within 12 months prior to current hospitalisation	Binary If yes, type ('Antiviral drug', 'Anti-RSV-antibodies', 'Other'), brand and date (month/year) if anti-RSV-monoclonal antibody
Laboratory results (RSV)	Type of specimen(s), date(s), RSV subtype(s)
Laboratory results (SARS-CoV-2)	Type of specimen(s), date(s), genetic variant(s)
Laboratory results (Influenza)	Type of specimen(s), date(s), subtype(s)
Laboratory results (other pathogens)	Type of specimen(s), date(s), identified pathogen(s), subtype(s) and genotype(s) [if applicable]
RSV RADT done in the 10 days prior to current hospitalisation	Binary. If yes, test result (positive, negative, no information) and date

* Definitions for each chronic condition are specified in the id.DRIVE Common dataset case report form.

† Clinical Frailty Scale version 2.0, developed by Dalhousie University, Halifax, Canada (<https://www.dal.ca/sites/gmr/our-tools/clinical-frailty-scale.html>). Clinical frailty scale is only collected by Study Contributor Henri-Mondor for patients 65 years and older based on the patient's premorbid status prior to the current SARI episode.

Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ECMO, extracorporeal membrane oxygenation; ESKD, end-stage liver disease; ESKD, end-stage kidney disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HIV, human immunodeficiency virus; ICU, intensive care unit; RSV, respiratory syncytial virus; RADT, rapid antigen detection test; SARI, severe acute respiratory infection; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

11.8 Data sources

The data source(s) per Study Contributor for exposures, outcomes (i.e., endpoints) and covariates are summarised in Table 3. below.

**Table 3. Data sources per Study Contributor for exposures, outcomes (i.e., endpoints) and covariates**

Study Contributor (Country)	Vaccine exposure	Laboratory-confirmed RSV infection	RSV subtypes A and B	ICU Admission	In-hospital death	Respiratory support levels	Covariates
Study Contributor name	«Specify source, e.g., Vaccine registry»	«Specify source, e.g., Laboratory records based on routine testing for RSV»	«Specify source, e.g., Additional RSV subtyping for the study»	«Specify source, e.g., Hospital medical records»	«Specify source, e.g., Hospital medical records»	«Specify source, e.g., Hospital medical records»	«Specify source, e.g., Hospital medical records»

Abbreviations: ICU, intensive care unit; RSV, respiratory syncytial virus.

11.9 Sample size considerations

The technical considerations for the calculation of the targeted samples sizes are detailed in ANNEX 1: SAMPLE SIZE CALCULATIONS, TECHNICAL SPECIFICATIONS.

In case the parameter settings used for these sample size calculations are very different from what is observed in the study, the sample size calculations will be updated accordingly with the progress reports.

11.10 Data management

Data collection, statistical analysis and preparation of the study report are activities firewalled from vaccine companies to avoid perception of undue influence on the study report and VE results interpretation.

11.10.1 Data management at Study Contributor level

Each Study Contributor is responsible for the data collection and data management of their participant-level study data. Depending on the Study Contributor, the data collection and source documentation will be different. A Source Data Location Form for variables is collected during a site initiation visit (SIV).

11.10.2 Data flow

1. The Study Contributor collects the data and enters/uploads it in the Castor® electronic data capture (EDC) system.
2. The Study Sponsor validates the data, raises applicable queries and the Study Contributor responds to data queries by updating or confirming the data.
3. The Study Sponsor imports the data from all participating Study Contributors in a secure environment using the EDC system's export functionality.
4. The Study Sponsor transforms all data to generate the output as prespecified in the SAP within the secure environment.

P95 reviews the imported variables on a bi-weekly basis. These data review checks are detailed in a Data Validation Plan.

A DMP is written prior to the start of the data collection to describe data management at the central level. The DMP describes all functions, processes, responsibilities and specifications for data collection, data storage, quality checking, transfer, cleaning, and validation. The DMP is updated regularly. All statistical analyses will be conducted in the id.DRIVE research server.

11.11 Data analysis

A complete and detailed SAP will be developed prior to the conduct of the analysis. The SAP specifies all statistical analyses, including sensitivity analyses, to be conducted, and will include tables shells and mock figures.

11.11.1 Context information

Context information will be provided in study reports by describing the circulating RSV subtypes during the study period in the countries (or regions) where the Study Contributors are located. National (or regional) RSV vaccination recommendations over time will be described (including licensed age groups, contraindications, number of doses and timing between doses). The external data sources used to describe the RSV viral distribution, vaccination coverage, and vaccination recommendations will be specified in the SAP.

11.11.2 Attrition diagram

The study report(s) will include an attrition diagram. The attrition diagram describes the number of records excluded from the statistical analyses, by reason of exclusion.

11.11.3 Descriptive analysis of demographics and baseline characteristics

Visualisations based on the final vaccine brand/product-specific data for analysis will be created including:

- number of test-negative controls and test-positive cases (possibly by RSV subtypes) over time
- distribution of covariates among controls and cases

A tabular summary based on the final brand/product-specific data for analysis will be created, describing the characteristics of cases and controls as predefined in the SAP.

11.11.4 Statistical analyses

11.11.4.1 Vaccine effectiveness analyses

VE is defined as $(1 - OR) \times 100\%$, where OR denotes the (exposure) odds ratio, comparing the confounder-adjusted odds of vaccination among RSV-positive study participants to the odds of vaccination among RSV-negative study participants. The analysis will evaluate VE among those vaccinated with the RSV vaccine of interest versus those unvaccinated. Those who were recently vaccinated with the RSV vaccine of interest, or vaccinated with other RSV vaccine(s) will be excluded from all VE analyses.

VE estimates will be adjusted for symptom-onset date at minimum, and additionally the following confounders – age, sex, and comorbidities (e.g. number of chronic conditions). Other potential covariates may be identified and included in the model using model building techniques. Confounder adjustments are usually achieved through inclusion of the relevant terms in the logistic regression models, with (penalised) spline terms for calendar time and age. However, other methods may be considered as well.

Differences between countries and Study Contributor are a potential source of heterogeneity and confounding. This can be accounted for using generalised additive models (GAM) or generalised estimating equation (GEE) models, with independent working correlation structures and with clusters being defined at the Study Contributor level. If some Study Contributors are networks that have hospitals which are very different (e.g. geographically separated), then clustering could be defined at the hospital level for these networks. However, similarities between these hospitals may remain due to being part of the same hospital network, in which cases these would not be treated as being independent of each other.

An important choice is whether the exposure odds ratios are desired to have a subject-specific (SS) or population-averaged (PA) interpretation [16]. The SS OR compares odds of vaccination among the RSV-positive cases to the odds of vaccination among the RSV-negative controls from the same Study Contributor (conditional on other covariates) and necessitates the inclusion of a fixed-effect or a random-effect term for Study Contributor in a multivariable model, or via a meta-analysis. The PA OR compares the odds of vaccination among the RSV-positive cases across the Study Contributors to the odds of vaccination among RSV-negative controls across the Study Contributors (conditional on other covariates) and is commonly obtained from a GEE model. Care should be taken with regards to method selection (estimators for point-estimates and standard errors) to avoid biased VE estimates when the clustering variable is a potential confounder or when the cluster size is informative. For PA estimates, GEE with a working independence correlation structure (IEE, or independence estimating equations) and cluster robust standard errors (Liang-Zeger) should be used. For subject-specific estimates, using a fixed-effect term for Study Contributor in a multivariable logistic regression model (GAM) is recommended due to its ease of implementation; no further adjustments to the standard errors are required.

If effect modification / treatment effect heterogeneity by Study Contributor is of interest, a stratified analysis by Study Contributor can be carried out. Alternately, Study Contributor-specific VE estimates can be obtained by adding interaction terms between Study Contributor and exposure in the models.

Matched cohort and matched analysis can be considered if sample size allows, e.g., matching by Study Contributor and hospital admission date.

11.11.4.2 Missing values

Given that the RSV status and exposure status is part of the primary data collection, it is anticipated that test results and exposure status should be available for nearly all

subjects. However, data on potential confounders may be missing for a portion of subjects. These details are typically obtained from pre-existing medical records, which existed before the SARI episode. Consequently, it is reasonable to assume that the missing completely at random mechanism holds. If the described missing data mechanism holds, performing a complete case analysis (CCA) will not lead to biased results. The primary analysis will therefore be a CCA, dropping records with missing information for the outcome, exposure of interest or the covariates. In case >10% of the cases and controls have missing covariate information, CCA is likely to be inefficient and alternatives such as multiple imputation and augmented CCA will be explored. A sensitivity analysis will be carried out comparing results from CCA (where records with missing data are dropped) and full set analysis (with imputed data).

11.11.4.3 Sensitivity analyses

Multiple sensitivity analyses will be performed. Alternative statistical models may be used that differ from models used for the primary and secondary objectives.

Additional sensitivity analyses that can be conducted include:

- Exploring the effects of different SARI definitions (id.DRIVE case definition¹¹, WHO-RSV case definition¹²),
- Exploring the effects of alternative sample types to evaluate the potential impact of respiratory specimens in detecting RSV.
- Exploring the effect of varying time between hospitalisation and date of swabbing to evaluate the potential impact of nosocomial infections.
- Exploring the effects of including participants co-enrolled in interventional trials.
- Exploring the effects of restricting the dataset to patients hospitalised primarily for respiratory infection.

¹¹ An id.DRIVE definition of SARI (defined as requiring hospitalisation with a suspicion of a respiratory infection with symptom onset within the last 14 days prior to hospital admission, having at least one of the following symptoms: cough, shortness of breath, fever ($\geq 38\text{ C}^\circ$) or sudden onset of anosmia, ageusia or dysgeusia) will be used in sensitivity analyses. This SARI definition is modified from the latest ECDC case definition (specifying “suspicion of respiratory infection”). EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (2023). Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 2.0. Available from: <https://www.ecdc.europa.eu/en/publications-data/core-protocol-ecdc-studies-covid-19-vaccine-effectiveness-against-0> [Accessed: 17-08-2023]].

¹² A World Health Organisation (WHO)-expanded definition of RSV-SARI (severe disease – defined as requiring hospitalisation AND acute – defined as onset within the last 10 days AND respiratory infection – defined as having at least one of the following: shortness of breath or cough) will be used in sensitivity analyses. [Source: <https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance/case-definitions>]

- Exploring the effects of restricting the dataset to patients who were LTCF residents prior to hospitalisation as a proxy of frailty.
- Exploring the effects of excluding outlying and influential Study Contributors.
- Exploring the effect of excluding the patients who have received monoclonal antibodies and other RSV products for either treatment or pre- or post-exposure prophylaxis prior to hospitalisation if there is significant use thereof in the population,
- Exploring unmeasured confounding or biases through negative control methods: negative control exposure and/or negative control outcomes (e.g., exclusion of test-negative controls that tested positive with RADT in the 10 days prior to hospital admission),
- Exploring the effect of patients having ≥ 2 laboratory-confirmed RSV infections in the current season.

All sensitivity analyses will be prespecified in the SAP.

12 QUALITY MANAGEMENT

12.1 Independent Scientific Committee

The ISC is composed of independent external experts (from organisations or institutions which are not partners of id.DRIVE) with good expertise/experience relevant for id.DRIVE studies on infectious diseases, vaccines, related preventive measures and therapeutics for infectious diseases in Europe.

The roles and responsibilities of the ISC are the following:

- reviews and makes recommendations for Master Scientific Documents (Study Master protocols and SAPs),
- reviews and makes recommendations for Study reports.

12.2 Quality Assurance and Audit Committee

The Quality Assurance and Audit Committee (QAAC) of id.DRIVE composed of one quality assurance expert of each Pharmaceutical Company Partner and one quality assurance expert of the Co-Coordination. The QAAC's mission is to provide, at the partnership level, guidance on implementation, conduct, monitoring and quality assurance of the Studies, as well as to ensure that data quality is in line with the Study request and to, when necessary and to the extent possible, identify areas for improvement.

The QAAC seeks to develop and sustain a reasonable and feasible mechanism to support quality management together with P95 as the Study Sponsor of the Studies.

The QAAC provides quality management recommendations for Study Contributors and oversees any audit at the Study Contributor level if needed; the audit is subcontracted to an external qualified consultants' auditor.

12.3 Monitoring

Monitoring activities include:

- Before study start, the Study Contributor will be asked to complete a quality management questionnaire to inform the Study Team on all aspects of the study conduct.
- Before study start, an SIV will be organised by the Study Team.
- During study conduct, regular Study Contributor contacts will be organised to monitor study progress (number of cases and controls enrolled), to ensure regular data input to the id.DRIVE EDC system and to discuss potential protocol deviations or other issues related to the study conduct.
- Study Contributors will be asked to keep high-level Screening Logs (including number of modified-SARI patients missed or not consented for the study with age group and sex), as they may affect interpretation of trend data.

- Monitoring shall occur as described in the id.DRIVE Monitoring Plan.

The Study Contributor investigators must permit any external auditor mandated by the QAAC of the id.DRIVE partnership or the Study Requestor, the IEC, auditors and representatives from regulatory authorities direct access to all study-related documents. Participant confidentiality will be protected at all times.

12.4 Data quality checks at central level

Programmed checks are run on Castor®-extracted data and the identified data issues are manually queried in Castor® every two weeks. After the Study Contributor responds to the queries by updating or confirming the data entered in Castor®, P95 Clinical and Epidemiology Services closes the queries. Per agreement, the identified data issues are also sent in an MS Excel document to the corresponding Study Contributors. All the queries should be closed before database lock.

13 LIMITATIONS OF THE RESEARCH METHODS

- Due to high demand and limited vaccine supplies, European countries often prioritise high-risk groups such as the elderly, residents in care facilities, and those with specific chronic conditions. This prioritisation creates potential confounding factors in studies on VE.
- Untangling waning of vaccine-induced immunity, varying VE against different RSV subtypes, and infection-acquired immunity is challenging due to the complex interaction of these factors.
- Infection-acquired immunity protects against re-infection but may wane and act as an effect modifier of VE. Hybrid immunity, combining infection-acquired and vaccine-induced immunity, is suggested for optimal protection against severe disease. However, identifying past RSV infection poses challenges due to potential underreporting or misclassification, especially with clinical-based diagnoses and the absence of serological results. This prior infection status could also introduce confounding, influencing vaccination decisions.
- The TNCC study design minimises unmeasured confounding tied to general health care-seeking behaviour [24]. However, specific health practices may still confound results. Vaccination uptake may be higher among individuals strongly adhering to preventive practices such as social distancing, reducing natural infection risk. Conversely, being vaccinated may lead to a false sense of security, relaxing precautions and increasing exposure risk. Additionally, those likely to get vaccinated against RSV may also favour influenza, SARS-CoV-2, and/or pneumococcal vaccinations, potentially biasing results. Sensitivity analyses redefining control groups will explore this bias. In this study, exposure ascertainment is based on multiple sources including vaccine registries, vaccination cards and medical records. Although vaccination status captured in medical records is neither validated against primary records nor validated verbally with the patient, misclassification is likely to be limited: complete exposure data is required for a participant to be retained in the id.DRIVE study (mandatory variables included date of administration, dose number and vaccine brand).
- The PROMISE generic RSV VE protocol recommends the exclusion of persons with a contraindication to the RSV vaccine being studied in order to only capture the eligible population. Such patients are not excluded from the present study as vaccine contraindications cannot be collected. However, numbers are expected to be small.
- RT-PCR has a high specificity and sensitivity if sufficient viral load is present in the sample, however, a single respiratory swab may miss around a half of RSV infections among older adults [17]. Diagnostic inaccuracies pose potential bias, influenced by factors like sampling technique, specimen type, number of specimens [18, 17], and timing with respect to symptom onset. In RSV RT-PCR, declining sensitivity over time may yield more false negatives, potentially underestimating VE as false-negative RSV infection cases would be included in the control group. Sensitivity analyses, such as varying the amount of time allowed between symptom onset and sampling, as well as addition of pre-

admission RADT, will explore potential misclassification bias. Study staff follow guidance for proper specimen collection, ensuring a robust testing procedure.

- Unaccounted potential confounders in this study, such as ethnicity and socio-economic status, could lead to biased VE estimates when certain groups are less likely to be vaccinated. TNCC studies, limited to those accessing healthcare or hospitalised, may not generalise to disadvantaged groups with poor access or nursing home residents, affecting result applicability to the general population.
- Estimating sample sizes for brand-specific VE is challenging due to unpredictable and evolving attack rates and vaccination coverage. This challenge is exacerbated by the increasing fragmentation of the vaccine market with more available RSV vaccination products. Despite our study's extensive European hospital network, obtaining sufficient samples for accurate estimates of primary and secondary objectives may be challenging.
- RSV monoclonal antibodies or other RSV vaccines or therapies may be used in the population. These products may prevent infection or its severity preventing hospitalisation, and lead to disease misclassification due to its effects on sampling and testing. To explore any potential bias due to disease misclassification, sensitivity analyses regarding use of prophylaxis prior to hospitalisation can be conducted.
- Time-varying confounders and effect modifiers, including seasonality, RSV subtypes, levels of vaccine-induced and natural immunity in the population, and timing of RSV vaccination programmes and their complex interplay makes it challenging to disentangle waning of vaccine-induced immunity, differences in VE against different RSV subtypes, and infection-acquired immunity. We will do stratified analysis for RSV subgroups, and control for seasonality in the analysis to mitigate this limitation.
- As a multi-centre study with numerous hospital sites across Europe, heterogeneity of the study population could be of concern. Indeed, inter- and intra-country differences may exist with regards to vaccine recommendations, vaccine roll-out, RSV epidemiology, population characteristics, and healthcare systems. These differences may lead to clustering at country or Study Contributor level. However, several steps are taken to reduce or take into account these potential sources of bias. Firstly, a single common eCRF is used across all Study Contributors with clear instructions to limit variation in interpretation and data collection. Second, the GEE model accounts for potential intra-cluster correlation among subjects from the same Study Contributor. Finally, in a sensitivity analysis, influential or outlying sites will be excluded in a leave-one-out procedure to re-estimate VE, as detailed in SAP.
- Co-vaccination with RSV, influenza, COVID-19: COVID-19 and influenza VE test-negative studies with influenza and SARS-CoV-2 acute respiratory infection (ARI) controls, respectively, underestimate VE if vaccine-preventable disease-related events are included in the control group [20]. Although this study explores excluding the controls who tested positive for influenza and SARS-CoV-2 via means of sensitivity analysis, to minimise the potential bias of correlated vaccine exposures for respiratory vaccine-preventable diseases, these principles may be generalised to other vaccine-preventable ARI (e.g.

pneumococcal disease) aetiologies that we are not able to capture in the study multiplex assay. We may be able to include pneumococcal vaccination in our models to test any effect of this variable on our VE estimate.

- Self-testing prior to admission could cause selection bias if it alters a patient's likelihood of presenting for care and being admitted to hospital. For example, if a physician is more (or less) likely to recommend admission based on a home self-test. This bias could be particularly harmful if the propensity to use home self-tests is correlated with vaccination status.

14 ETHICAL AND REGULATORY CONSIDERATIONS, RETENTION OF DATA AND OF BIOLOGICAL SAMPLES

14.1 Guiding principles

To ensure the quality and integrity of research, this study will be conducted under the International Ethical Guidelines on Epidemiological Studies issued by the Council for International Organisations of Medical Sciences (CIOMS) [21], Good Epidemiological Practice (GEP) [22], the ethical principles that have their origins in the Declaration of Helsinki, and any applicable national laws, regulations and guidelines.

This is an observational study. Therefore, there is no direct benefit to the participants. Nevertheless, there are important potential societal benefits derived from this VE study. Close monitoring of the effectiveness of RSV vaccination products is essential to guide decision-making regarding vaccination products marketing approval, optimisation of vaccination programmes and future RSV vaccine development.

14.2 Ethics approval

The Study Contributor-specific protocols will be submitted to relevant IECs following local regulations and the declaration of Helsinki. Copies of the appropriate IEC approvals will be collected from each Study Contributor and archived according to the local regulations, but at least for 10 years. The only exception is where the study is part of an ongoing routine programme evaluation required by a ministry of health or a requisite part of the public health institution's work and would therefore fall outside the mandate for IECs. In these cases, a statement that no formal approval from an IEC is required is sufficient.

14.3 Informed consent

Written informed consent will be obtained from all participants/guardians as specified by the national/regional IEC, if applicable. The following information should be specified in the informed consent form (ICF) which will be translated in local language: who is responsible for the study, aim of the study, risk of study procedures nature of processed data, purposes of processing, purpose of the use of the data including potential future use of the data to advance knowledge on vaccines, recipients of possible data transfers, rights of the study participants, and consequences of not accepting the informed consent. When allowed by Ethics Committees, specific consent procedures may be needed for patients in poor health conditions (e.g., oral witnessed consent, consent by next of kin). If informed consent will not be required, the reason will be stated.

14.4 Independent ethics committee/Institutional review board

Consistent with local regulations and prior to enrolment of participants at a given Study Contributor, the study protocol together with its associated documents (e.g., ICF) will be submitted by the Study Contributor to the responsible institutional review board (IRB)/IEC for its review. Participant enrolment will not start before the Study Contributor has obtained written confirmation of a favourable opinion/approval from the relevant central or local IRB/IEC. The Study Contributor will promptly and before first participant enrolment inform the Study Team that ethical approval has been granted. The IRB/IEC will be asked to provide documentation of the date of the meeting at which the favourable opinion/approval was given that clearly identifies the study, the protocol version, and the ICF version reviewed.

Before implementation of any substantial changes to the protocol, protocol amendments will also be submitted to the relevant IRB/IEC in a manner consistent with local regulations. It is the responsibility of the Study Contributor (local) investigator to have prospective approval of the study protocol, protocol amendments, and ICFs, and other relevant documents, if applicable, from their local IRB/IEC and provide documentation of approval to the Study Team.

Should the study be terminated early for any unanticipated reason, the Study Contributor (local) investigator will be responsible for informing the IRB/IEC of the early termination.

14.5 Participant's confidentiality

Data will be pseudonymised at the Study Contributor level prior to data transfer to P95 Epidemiology & Pharmacovigilance. All parties will ensure protection of participants' personal data and will not include participant names on any study forms, reports, publications, or in any other disclosures, except where required by law. In accordance with local regulations in each of the countries, participants will be informed about data handling procedures and asked for their consent. Data protection and privacy regulations will be observed in capturing, forwarding, processing, and storing participant data. Every effort will be made to protect participant confidentiality according to Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons regarding the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation, GDPR).

14.6 Changes to the protocol

Changes to the protocol will be documented in written protocol amendments. Such protocol changes will be discussed and agreed upon with the Study Team prior to their implementation. Major (i.e., substantial, significant) amendments will usually require submission to the relevant IRB/IEC for approval or favourable opinion and to the relevant regulatory authorities, if applicable. In such cases, the amendment will be implemented only after approval or favourable opinion has been obtained.

Minor (non-substantial) protocol amendments, including administrative changes, will be filed at each participating Study Contributor and will be submitted to the relevant IRB/IEC or regulatory authorities where required by pertinent regulations.

14.7 Secondary data use

The data generated as part of this study may be used for future research related to the expansion of the knowledge, prevention and control of infectious diseases. For this secondary data use, id.DRIVE governance principles will be respected as detailed in the id.DRIVE Governance Charter. The Governance Charter can be made available by the Co-Coordination upon written request.

15 STUDY MANAGEMENT AND LOGISTICAL ASPECTS

This study will be performed by the Study Contributor investigator(s), with guidance, input, review, and approval of the Study Team, including development of materials, recruitment, training, management of network study sites (Study Contributors), EDC, data management and analysis.

The Study Contributor investigator(s) and all study staff will conduct the study in compliance with the final version of this protocol. The rights, safety and well-being of the participants are the most important considerations and prevail over the interests of science and society. All personnel involved in the conduct of this study must be qualified by education, training, and experience to perform their tasks.

15.1 Training

Study Contributor investigators and data collectors will be trained on the study protocol before the start of the study. They will receive the protocol and study training material.

15.2 Data capture

The data will be collected using an EDC system as described in the DMP.

15.3 Retention

To enable evaluations and/or audits from regulatory authorities or others, the Study Contributor investigator(s) agree(s) to keep documents and data relating to the study in an orderly manner in a secure study file, which will be available for audits/inspections, for a period of at least 10 years after the end of the study or longer according to local requirements and legislation. Documents to be archived include the participant enrolment log and the signed ICFs. In the event that archiving of the file is no longer possible at the Study Contributor, the Study Contributor/investigator will be instructed to notify the Study Team. The Study Contributor investigator must contact the Sponsor before destroying any study-related documentation. It is the responsibility of the Sponsor to inform the Study Contributor of when these documents no longer need to be retained.

Biological specimens might be collected for future research. Retention, storage, and access rights will be predefined and described as appropriate.

15.4 Discontinuation of study participation/Withdrawal from the study

Participation in the study is strictly voluntary. A participant has the right to withdraw from the study at any time and for any reason, without any negative impact on the quality of care or on the relationship with the treating doctor(s). All attempts should be made to determine the underlying reason for the discontinuation/withdrawal and,

if possible, the primary underlying reason should be recorded. Data collected up to the time of consent withdrawal will be considered for the analysis.

15.5 Study termination

The Study Team reserves the right to terminate the study at a specific Study Contributor at any time. Reasons for terminating the study include but are not limited to the following:

- The Study Contributor does not respond to study management requests.
- Repeated protocol deviations/poor protocol compliance.

16 REPORTING AND DISSEMINATION OF RESULTS

16.1 Study protocol

The study protocol and final study report will be included in the HMA/EMA catalogue of real-world data studies.

16.2 Management and reporting of adverse events/adverse reactions

This is an observational epidemiological study for assessing the effectiveness of recommended or routine RSV vaccination based on primary and secondary data collection. Treatments, vaccines, and pharmaceutical prevention will be collected as part of secondary data collection (registries and/or patient files). Therefore, no adverse events or adverse reactions are collected. The Study Contributors conducting the study should follow local requirements as regards the submission of cases of suspected adverse reactions to the competent authority in the country where the reaction occurred.

In case additional safety reporting is required for a specific Study Requestor, only serious adverse events (SAEs) related to the receipt of the investigational products, of which the Study Contributors become aware, will be reported to the Study Requestor. The individual case safety report form for reporting SAEs is provided in the Investigator Site Files.

16.3 Progress, interim and final reports

Progress reports will be provided to the Study Requestors every two months since enrolment of the first study participant. Progress reports will provide an overview of the number of cases, number of controls, number of study participants immunised with any RSV vaccination product brand and number of study participants immunised with the RSV vaccination product brand of interest.

Interim analysis for a specific VE objective will be performed as soon as a prespecified number of cases required for the brand-specific VE estimates is reached. The progress reports will be used to monitor this required number of cases.

A final study report will be written for the RSV vaccine. The study report(s) (interim and/or final, as applicable) will be submitted to the EMA by the Study Requestor depending on regulatory requirements. This process is further described in the id.DRIVE Governance Charter.

16.4 Publication

Scientific publication(s) of the study results will be prepared. Co-authorship will be defined following the International Committee of Medical Journal Editors (ICMJE) criteria and the Good Publication Practice (GPP). All publications will be open-access.

Study Contributors are allowed to develop publications based on their raw patient-level data or cleaned pseudonymised patient-level data collected in the scope of the id.DRIVE Study following the id.DRIVE Governance Charter.

17 FUNDING

id.DRIVE is a public-private partnership funded by the Pharmaceutical Company Partners and leveraging health capacities from public partners and sites. This generic Master Protocol has been developed by the id.DRIVE partnership, which has received funds from AstraZeneca, Bavarian Nordic, CureVac, GSK, Janssen, Moderna, Novavax, Pfizer, Sanofi, and Valneva, leveraging public health capacity from Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) and the Finnish institute for Health and Welfare (THL) and existing infrastructure at P95. Other Partners (Pharmaceutical Companies or other Institutions) may join the id.DRIVE partnership at later stages. Cost sharing principles are defined in the id.DRIVE Consortium governance charter. The execution of the brand-specific study will be further funded by the Study Requestor requesting the specific study.

18 REFERENCES

1. VAN ROEKEL, C., POUKKA, E., TURUNEN, T., et al. (2024). Effectiveness of Immunization Products Against Medically Attended Respiratory Syncytial Virus Infection: Generic Protocol for a Test-Negative Case-Control Study. *J Infect Dis*, 229(Supplement_1):S92-S9. DOI: <https://doi.org/10.1093/infdis/jiad483>.
2. WORLD HEALTH ORGANIZATION (2024). *RSV surveillance case definitions*. Available from: <https://www.who.int/teams/global-influenza-programme/global-respiratory-syncytial-virus-surveillance/case-definitions> [Accessed: 24-05-2024].
3. WORLD HEALTH ORGANIZATION (2023). *Respiratory Syncytial Virus (RSV) disease*. Available from: <https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/respiratory-syncytial-virus-disease> [Accessed: 23-11-2023].
4. LI, Y., KULKARNI, D., BEGIER, E., et al. (2023). Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study. *Infect Dis Ther*, 12(4):1137-49. DOI: <https://doi.org/10.1007/s40121-023-00792-3>.
5. SAVIC, M., PENDERS, Y., SHI, T., et al. (2023). Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. *Influenza Other Respir Viruses*, 17(1):e13031. DOI: <https://doi.org/10.1111/irv.13031>.
6. NGUYEN-VAN-TAM, J. S., O'LEARY, M., MARTIN, E. T., et al. (2022). Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. *Eur Respir Rev*, 31(166)DOI: <https://doi.org/10.1183/16000617.0105-2022>.
7. MAGGI, S., VERONESE, N., BURGIO, M., et al. (2022). Rate of Hospitalizations and Mortality of Respiratory Syncytial Virus Infection Compared to Influenza in Older People: A Systematic Review and Meta-Analysis. *Vaccines (Basel)*, 10(12)DOI: <https://doi.org/10.3390/vaccines10122092>.
8. IVEY, K. S., EDWARDS, K. M. & TALBOT, H. K. (2018). *Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults*. *J Am Coll Cardiol*, 71(14):1574-83. DOI: <https://doi.org/10.1016/j.jacc.2018.02.013>.

9. MELGAR, M., BRITTON, A., ROPER, L. E., et al. (2023). Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. *MMWR Morb Mortal Wkly Rep*, 72(29):793-801. DOI: <https://doi.org/10.15585/mmwr.mm7229a4>.
10. MEIJER, A., OVERDUIN, P., HOMMEL, D., et al. (2013). Outbreak of respiratory syncytial virus infections in a nursing home and possible sources of introduction: the Netherlands, winter 2012/2013. *J Am Geriatr Soc*, 61(12):2230-1. DOI: <https://doi.org/10.1111/jgs.12565>.
11. MCLAUGHLIN, J. M., KHAN, F., BEGIER, E., et al. (2022). *Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis*. *Open Forum Infect Dis*, 9(7):ofac300. DOI: <https://doi.org/10.1093/ofid/ofac300>.
12. BORCHERS, A. T., CHANG, C., GERSHWIN, M. E., et al. (2013). *Respiratory syncytial virus--a comprehensive review*. *Clin Rev Allergy Immunol*, 45(3):331-79. DOI: <https://doi.org/10.1007/s12016-013-8368-9>.
13. TEIRLINCK, A. C., BROBERG, E. K., STUWITZ BERG, A., et al. (2021). *Recommendations for respiratory syncytial virus surveillance at the national level*. *Eur Respir J*, 58(3) DOI: <https://doi.org/10.1183/13993003.03766-2020>.
14. BAGGA, B., WOODS, C. W., VELDMAN, T. H., et al. (2013). Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. *Antivir Ther*, 18(6):785-91. DOI: <https://doi.org/10.3851/IMP2629>.
15. EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL (2021). ECDC Technical report: Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, version 1.0, 2021. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/Core-protocol-for-ECDC-studies-of-COVID-19-vaccine-effectiveness-against-hospitalisation-with-SARI.pdf>. [Accessed: 24-05-2024].
16. KAHAN, B. C., LI, F., COPAS, A. J., et al. (2023). *Estimands in cluster-randomized trials: choosing analyses that answer the right question*. *Int J Epidemiol*, 52(1):107-18. DOI: <https://doi.org/10.1093/ije/dyac131>.
17. RAMIREZ, J., CARRICO, R., WILDE, A., et al. (2023). Diagnosis of Respiratory Syncytial Virus in Adults Substantially Increases When Adding Sputum, Saliva, and Serology

Testing to Nasopharyngeal Swab RT-PCR. *Infect Dis Ther*, 12(6):1593-603. DOI: <https://doi.org/10.1007/s40121-023-00805-1>.

18. ONWUCHEKWA, C., MOREO, L. M., MENON, S., et al. (2023). Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis. *J Infect Dis*, 228(2):173-84. DOI: <https://doi.org/10.1093/infdis/jiad012>.

19. YAO X., HAMILTON R.G., WENG N.P., et al. (2011). Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. *Vaccine*, 29(31):5015-21. DOI: <https://doi.org/10.1016/j.vaccine.2011.04.077>.

20. DOLL, M. K., PETTIGREW, S. M., MA, J., et al. (2022). Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors. *Clin Infect Dis*, 75(1):e564-e71. DOI: <https://doi.org/10.1093/cid/ciac234>.

21. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES & WORLD HEALTH ORGANIZATION (2009). *International Ethical Guidelines for Epidemiological Studies*. Available from: https://cioms.ch/wp-content/uploads/2017/01/International_Ethical_Guidelines_LR.pdf [Accessed: 23-11-2023].

22. HOFFMANN, W., LATZA, U., BAUMEISTER, S. E., et al. (2019). Guidelines and recommendations for ensuring Good Epidemiological Practice (GEP): a guideline developed by the German Society for Epidemiology. *Eur J Epidemiol*, 34(3):301-17. DOI: <https://doi.org/10.1007/s10654-019-00500-x>.

ANNEX 1: SAMPLE SIZE CALCULATIONS, TECHNICAL SPECIFICATIONS

Sample size calculation

The goal of the sample size calculations is to calculate the minimally-required sample size that ensures desirable properties of the VE estimates. Examples of desirable properties are the expected length of the 95% CI, the expected lower half width of the 95% CI or power to detect statistical significance of a prespecified effect size. Two approaches to sample size calculations have been developed; analytical and simulation-based. While analytical methods do have the advantage of computational speed, simulation-based methods are sometimes developed to closer mimic the actual study design than proposed analytical approaches at the cost of requiring additional parameter assumptions.

Analytical approach: power and minimal detectable VE

The power is the likelihood of statistical significance when there is a true effect while the minimal detectable VE is the smallest VE that can be detected as significantly greater than zero in a given study using hypothesis testing. The power and minimal detectable VE can be derived from the 2x2 table of interest cross-tabulating the expected number of cases and controls with the expected number of subjects within the relevant exposure group and within the appropriate comparator group.

Particularly, to derived the power for case-control studies, first calculate

$$M = \left| \frac{(\lambda - 1)(P - 1)}{1 + (\lambda - 1)P} \right|,$$

and

$$p_c^* = \frac{P}{r + 1} \left(\frac{r\lambda}{1 + (\lambda - 1)P} + 1 \right),$$

where λ is the relative risk, P is the exposure prevalence and r is the case-control ratio. Then, the power can be derived from

$$z_\beta = \frac{\frac{MP\sqrt{nr}}{\sqrt{r+1}} - z_\alpha \sqrt{(r+1) p_c^* (1 - p_c^*)}}{\sqrt{\frac{\lambda P(1-P)}{[1 + (\lambda - 1)P]^2} + r P (1 - P)}},$$

where z_α and z_β are critical values for the standard normal distribution¹³.

The minimal detectable VE for a case-control study is estimated as

$$VE_{MD} = 1 - RR_{MD(RR < 1)}, \quad (1)$$

where $RR_{MD(RR < 1)}$ is the minimal detectable approximate relative risk (RR) in a case-control study, if $RR < 1$, or

$$RR_{MD(RR < 1)} \cong 1 + \frac{-b - \sqrt{b^2 - 4a(r+1)}}{2a}, \quad (2)$$

where

$$a = r\gamma^2 - \frac{Nr\gamma(1-\gamma)}{\left(\frac{z_\alpha + z_\beta}{2}\right)^2(r+1)}; b = 1 + 2r\gamma,$$

for 'cases to controls' ratio r , coverage γ , total number of subjects N , and where z_α and z_β are the standard normal z-scores for the type I and type II error rates¹³.

For case-control studies with multiple exposure categories ($k > 2$), 3 generic exposure categories exist: (1) the exposure group of interest, (2) the appropriate comparator group and (3) other exposure groups not relevant for the comparison, resulting in a 3x2 cross table. Starting from the assumptions on the case-control ratio and on the proportions of subjects belonging to each of the three exposure categories (derived from assumptions on brand-specific vaccination coverage, overall vaccination coverage and vaccination history), the relative cell frequencies of the 2x2 table of interest can be derived, based on which all parameters required for sample size calculations are derived.

Simulation-based approach

Data generation workflow

Notation

Before describing the data generation workflow, the following parameters which act as input for the model have to be defined:

1. $VE_{x,overall}$: the overall VE of exposure x , the corresponding odds ratio is $OR_{x,overall} = 1 - \frac{VE_{x,overall}}{100}$.
2. $c = P(unexposed|control)$: proportion of unexposed subjects among the controls

¹³ WOODWARD, M. (2013). Epidemiology: Study Design and Data Analysis, 3rd Ed., Chapman and Hall/CRC.



3. $P_x = P(\text{exposure } x | \text{exposed, control})$: brand share of exposure x among the exposed
4. r : ratio of cases to control (that is, number of cases per one control)

General set-up

In each simulation run, a dataset is constructed by combining data generated for a number of individual Study Contributors. We will denote the total number of Study Contributors as k and the total sample size as N . Additionally, it is assumed that each Study Contributor contributes the same number of subjects, i.e. $\frac{N}{k}$. In order to allow for variability in the underlying vaccine effects across Study Contributors, the VE can be different from Study Contributor to Study Contributor. In the next section, it is described how data for one Study Contributor is generated given the Study Contributor-specific VEs for all exposures. The subsequent section describes how the VE are varied across the Study Contributors to introduce between-Study Contributor variability.

Simulating data at the Study Contributor level

For each Study Contributor, $\frac{N}{k} \times \frac{r}{1+r}$ cases and $\frac{N}{k} \times \frac{1}{1+r}$ controls are simulated. The vaccine exposure status for the controls is generated from a multinomial distribution with the probability of being unexposed equal to c and the probability of being exposed to brand x equal to $(1 - c)P_x$.

For each $\frac{N}{k} \times \frac{r}{1+r}$ of the cases, the vaccine exposure status is then generated from a multinomial distribution with the probability of being unexposed equal to success probability of

$$P(\text{unexposed} | \text{case}) = \frac{1}{1 + \sum_x \text{OR}_x * \frac{(1-c)P_x}{c}}$$

equal to $P(\text{exposure } x | \text{case}) = \text{OR}_x * \frac{(1-c)P_x}{c} * P(\text{unexposed} | \text{case})$.

Simulating Study Contributor-specific VE

Effect of primary series vaccination

To incorporate the expected between-Study Contributor heterogeneity, for each Study Contributor, a Study Contributor-specific odds ratio ($\text{OR}_{x,\text{site}}$) was generated from a log-normal distribution with a median of $1 - \frac{\text{VE}_{x,\text{overall}}}{100}$ and variance on the log scale of 0.05. The value of the variance parameter on the log scale was selected to be 0.05 as it introduced an amount of between-Study Contributor heterogeneity and was in line with the heterogeneity seen in a previous database

study¹⁴. Note that decreasing the value of this parameter lead to a decrease in the sample size requirements. The expected value of the VE over the Study Contributors is then equal to $100 \times \left(1 - \exp\left(\log\left(1 - \frac{VE_{x,overall}}{100}\right) + \frac{0.05}{2}\right)\right)$.

Effect of additional dose vaccination

The overall effect of the exposure corresponding to vaccination with a primary series and an additional dose is generally derived from the VE of the primary series and the relative vaccine effectiveness (rVE) of the additional dose, $rVE_{additional\ dose\ vs\ primary}$, using the following relation

$$VE_{additional\ dose} = 100 \times \left(1 - \left(1 - \frac{rVE_{additional\ dose\ vs\ primary}}{100}\right) \left(1 - \frac{VE_{primary\ series}}{100}\right)\right).$$

To incorporate the expected study heterogeneity of the effect of an additional dose, the same procedure as for the primary series is used.

Estimates and data obtained for each simulation

For each simulated dataset, an estimate of the (r)VE and the corresponding 95% CI is obtained using one of the following procedures:

Two-stage pooling / random-effects meta-analysis (RE-MA)

- The simulated dataset is restricted to represent the data of interest.
- The Study Contributor-specific expected OR on the log scale of the (relative) treatment effect is calculated using a logistic regression model with the disease status as the outcome and the exposure status as a covariate.
- The Study Contributor-specific log OR estimates are combined using a RE-MA model. More particularly, the log OR estimates are combined using the Hartung-Knapp-Sidik-Jonkman estimator to obtain an estimate of the median overall log OR and the corresponding two-sided 95% CI.
- The pooled log OR and the corresponding CI are then back-transformed to obtain an estimate and 95% CI of the median overall VE.
- The overall VE estimate and the length of the CI are stored for each simulation.

Generalised estimation equations (GEE)

- The simulated dataset is restricted to represent the data of interest.

¹⁴ THOMPSON, M. G., STENEHJEM, E., GRANNIS, S., et al. (2021). Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med, 385(15):1355-71. DOI: <https://doi.org/10.1056/NEJMoa2110362>.

- The expected OR on the log scale of the treatment effect is estimated using a logistic regression model with the disease status as the outcome and the exposure as a covariate. The estimates are obtained using the GEE method in which the Study Contributors are considered as clusters and the variances are calculated using a robust sandwich estimator.
- The estimated log OR and the corresponding CI are then back-transformed to obtain an estimate of the mean overall (r)VE and its 95% CI.
- The overall (r)VE estimate and the length of the CI are stored for each simulation.

Generalised linear model/generalised additive model (GLM/GAM)

- The simulated dataset is restricted to represent the data of interest.
- The expected OR on the log scale of the treatment effect is estimated using a logistic regression model with the disease status as the outcome and the exposure as a covariate.
- The estimates are obtained using the GLM/GAM method in which the Study Contributors are considered as fixed effects.
- The estimated log OR and the corresponding CI are then back-transformed to obtain an estimate of the mean overall (r)VE and its 95% CI.
- The overall (r)VE estimate and the length of the CI are stored for each simulation.

Number of simulations performed

For each combination of parameter settings, a total of 500 simulations are recommended. On empirical basis, this number of simulation runs leads to stable Monte Carlo CIs while limiting the computational burden.

Summary measures of the simulation study

For each combination of the study characteristics, the measure of interest is obtained from the 500 simulations, e.g.

- The expected range of the 95% CI is defined as the mean range of the CI obtained from the 500 simulations.
- The expected lower half width of the 95% CI is defined as the mean lower half width of the CI obtained from the 500 simulations.
- The expected power to detect a VE significantly different from 0 is defined as the proportion of the CIs that do not include 0.

For each measure, 95% Monte Carlo CIs were constructed based on the respective Monte Carlo standard errors observed in the simulations.ve Monte Carlo standard errors observed in the simulations.

ANNEX 2: PATIENTS LACKING CAPACITY

According to the UK Mental Capacity Act 2005 (c. 9) Part 1, a person is considered to lack mental capacity in relation to a matter if at the material time he is unable to make a decision for himself in relation to the matter because of an impairment of, or a disturbance in the functioning of, the mind or brain. For the purpose of this study, a patient is considered to lack capacity if, at the time of consenting for the study, they are unable to fully understand, retain, or process the information necessary to make an informed decision about their participation in the study because of this mental impairment or disturbance due to a condition other than SARI. For these patients, consent from the next of kin cannot be used, and they will therefore be excluded from the study. The following aspects need to be considered when assessing the participant's mental capacity:

- A lack of mental capacity cannot be established merely by reference to a person's age or appearance, or a condition of his/her, or an aspect of his/her behaviour, which might lead others to make unjustified assumptions about his/her mental capacity.
- A person is unable to make a decision for himself/herself if he/she is unable to:
 - a) understand the information relevant to the decision,
 - b) retain that information,
 - c) use or weigh that information as part of the process of making the decision, or
 - d) communicate his/her decision (whether by talking, using sign language or any other means).
- A person is not to be regarded as unable to understand the information relevant to a decision if he/she is able to understand an explanation of it given to him/her in a way that is appropriate to his/her circumstances (using simple language, visual aids, different language or any other means).
- The fact that a person is able to retain the information relevant to a decision for a short period only does not prevent him/her from being regarded as able to make the decision. The information relevant to a decision includes information about the reasonably foreseeable consequences of:
 - a) deciding one way or another,
 - b) failing to make the decision.

For avoidance of doubt, patients who temporarily lack mental capacity only due to SARI (e.g., who are in coma in intensive care unit), can still be included in the study.